Solu Therapeutics
Solu Therapeutics is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, pioneering a novel class of antibody therapeutics that unlock cell-surface targets by combining small molecules with effector antibodies through proprietary linker technology. Its two platform technologies are CyTAC (Cytotoxicity Targeting Chimera), which links cell-surface targets to antibodies that kill pathogenic cells, and TicTAC (Therapeutic Index Control Targeting Chimera), which gives long-acting small-molecule agonists and antagonists antibody-like pharmacokinetics. Its lead program, STX-0712, is a CyTAC targeting the GPCR CCR2 in Phase 1 trials for chronic myelomonocytic leukemia, with additional oncology and immunology programs advancing. Solu is a portfolio company of the venture firm DCVC. The company operates as a drug-discovery and clinical-development organization and publishes no public developer API, developer portal, or programmatic surface.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Solu Therapeutics the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Solu Therapeutics scores 11.0/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Solu Therapeutics
Each block below is one kind of artifact we hold for Solu Therapeutics. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Solu Therapeutics — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Commercial 2
Pricing, plans, and the legal terms of use
Company 1
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/solu-therapeutics · machine-readable index on apis.io